Neovacs Begins a Phase I/II Clinical Trial for the Treatment of Crohn’s Disease
News Nov 04, 2008
Neovacs has announced that it had begun a phase I/II clinical study at three study centres in South Africa with the candidate TNFa-kinoid, a therapeutic vaccine for the treatment of TNFa dependent auto-immune diseases such as rheumatoid arthritis, Crohn’s disease and psoriasis.
This study, to be conducted on patients suffering from Crohn’s disease, will relate to the identification of the optimal immunogenic dosage for neutralizing TNFa.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE